Biomet

Purpose

Determine the safety and efficacy of the Comprehensive Shoulder System with Nano humerol component in total shoulder arthroplasty

Criteria

Contact Principal Investigator for Information

Details

Patients age 21-90years old with non-inflammatory degenerative joint disease requiring total shoulder arthroplasty will be enrolled.  Patients will be randomly assigned to have either the Comprehensive Shoulder System with Nano humerol component or the Comprehensive Shoulder System with mini-stem component implanted.  Quality of life questionnaires will be completed at each visit.

Interested in more information? Contact Us:

Shane Barton, MD, Principal Investigator
The Orthopedic Clinic
(318) 212-8130

IRB: Willis-Knighton
IRB Number:
Trial Type: Device
Sponsor: Biomet